You have 9 free searches left this month | for more free features.

City

Beijing (1)

Phoenix (1)

Seoul (1)

Shanghai (1)

Wuhan (1)

Condition

Neovascular Age-Related Macular Degeneration (1)

Neovascular(Wet) Age Related Macular Degeneration (1)

Wet Age-related Macular Degeneration (1)

Overall Status

Completed (2)

Recruiting (1)

Sign in for free

Phase

phase 1 (2)

phase 3 (1)

Sponsor

Chong Kun Dang Pharmaceutical (1)

Retinal Consultants of Arizona (1)

Shanghai Biomabs Pharmaceutical Co., Ltd. (1)

Collaborator

Ophthotech Corporation (1)

Intervention

lucentis® (3)

avastin® (1)

ckd-701 (1)

cmab818 (1)

eylea® (1)

fovista™ (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (3)

lucentis®

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Wet Age-related Macular Degeneration Trial in Beijing, Wuhan, Shanghai (CMAB818, Lucentis®)

Recruiting

Wet Age-related Macular Degeneration

CMAB818
Lucentis®

Beijing, Beijing, China
+3 more

Jun 14, 2022

Neovascular(Wet) Age Related Macular Degeneration Trial in Seoul (CKD-701, Lucentis®)

Completed

Neovascular(Wet) Age Related Macular Degeneration

CKD-701
Lucentis®

Seoul, Korea, Republic of

Seoul National University Hospital

Apr 22, 2021

Neovascular Age-Related Macular Degeneration Trial in Phoenix (Fovista™, Lucentis®, Avastin®)

Completed

Neovascular Age-Related Macular Degeneration

Fovista™
+3 more

Phoenix, Arizona

Retinal Consultants of Arizona

Sep 20, 2018